Dilriva Inhalation Capsule 18 mcg
Dilriva Inhalation Capsule 18 mcg Uses, Dosage, Side Effects, Food Interaction and all others data.
Dilriva Inhalation Capsule 18 mcg is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3-receptors at the smooth muscle leading to bronchodilation. The bronchodilation following inhalation of Dilriva Inhalation Capsule 18 mcg is predominantly a site-specific effect.
Dilriva Inhalation Capsule 18 mcg is a long acting antimuscarinic that causes bronchodilation. The effects of tiotropium last over 24 hours and there is a wide therapeutic index as overdoses are uncommon even at doses well above the recommended maximum.
| Trade Name | Dilriva Inhalation Capsule 18 mcg |
| Availability | Prescription only |
| Generic | Tiotropium |
| Related Drugs | Dupixent, Xolair, ProAir Digihaler, Symbicort, Breo Ellipta, Ventolin, Xopenex, Ventolin HFA, Spiriva |
| Weight | 18 mcg |
| Type | Inhalation Capsule |
| Formula | C19H22NO4S2 |
| Weight | Average: 392.512 Monoisotopic: 392.099024577 |
| Protein binding | Tiotropium is 72% protein bound in plasma. |
| Groups | Approved |
| Therapeutic Class | Anticholinergic bronchodilators |
| Manufacturer | UniMed UniHealth Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | October 19, 2023 at 6:27 am |
Uses
Dilriva Inhalation Capsule 18 mcg is used for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Dilriva Inhalation Capsule 18 mcg is also used to associated treatment for these conditions: Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Airways Disease Exacerbated, Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Respiratory Diseases, Emphysema
How Dilriva Inhalation Capsule 18 mcg works
Dilriva Inhalation Capsule 18 mcg is an antagonist of muscarinic receptors M1 to M5. Inhibition of the M3 receptor in the smooth muscle of the lungs leads to relaxation of smooth muscle and bronchodilation.
Dosage
Dilriva Inhalation Capsule 18 mcg dosage
Adults and adolescents 12 years and older: The recommended dosage of Dilriva Inhalation Capsule 18 mcg bromide is the inhalation of 2 puffsonce daily.
Side Effects
The most commonly reported adverse drug reaction was dry mouth. Dry mouth was usually mild and often resolved during continued treatment. Other reactions reported in individual patients and consistent with possible anticholinergic effects included constipation, increased heart rate, blurred vision, glaucoma, urinary difficulty, and urinary retention.
Toxicity
Symptoms of overdose include altered mental status, tremors, abdominal pain, and severe constipation. However, doses of up to 282µg did not lead to systemic anticholinergic effects in a trial of 6 patients. In case of overdose, stop tiotropium and being symptomatic and supportive therapy.
Precaution
As an anticholinergic drug, Dilriva Inhalation Capsule 18 mcg may potentially worsen symptoms and signs associated with narrow angle glaucoma, prostatic hyperplasia or bladder-neck obstruction and should be used with caution in patients with any of these conditions. As a predominantly renally excreted drug, patients with moderate to severe renal impairment treated with Dilriva Inhalation Capsule 18 mcg should be monitored closely.
Eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema may be signs of acute narrow angle glaucoma. Should any of these signs and symptoms develop, consult a physician immediately. Miotic eye drops alone are not considered to be effective treatment.
Interaction
Dilriva Inhalation Capsule 18 mcg has been used concomitantly with other drugs commonly used in COPD without increases in adverse drug reactions. These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. However, the co-administration of Dilriva Inhalation Capsule 18 mcg with other anticholinergic-containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.
Food Interaction
- Take with or without food. Food is not expected to interfere with absorption.
Dilriva Inhalation Capsule 18 mcg Drug Interaction
Moderate: albuterol / ipratropium, albuterol / ipratropiumUnknown: fluticasone / salmeterol, aspirin, aspirin, omega-3 polyunsaturated fatty acids, fluticasone nasal, furosemide, metoprolol, metoprolol, polyethylene glycol 3350, nitroglycerin, acetaminophen, albuterol, budesonide / formoterol, albuterol, albuterol, cyanocobalamin, ascorbic acid, cholecalciferol
Dilriva Inhalation Capsule 18 mcg Disease Interaction
Moderate: angioedema, anticholinergic effects, tachycardia, liver, renal dysfunction
Volume of Distribution
The volume of distribution of tiotropium is 32L/kg.
Elimination Route
33% of an inhaled solution reaches systemic circulation, while oral solutions have a bioavailability of 2-3%. A dry powder for inhalation is 19.5% bioavailable. Dilriva Inhalation Capsule 18 mcg metered spray for inhalation reaches a maximum concentration in 5-7 minutes.
Half Life
The terminal half life of tiotropium is 24 hours in patients with COPD and 44 hours in patients with asthma.
Clearance
The total clearance of tiotropium is 880mL/min in healthy subjects receiving 5µg daily. The renal clearance of tiotropium was 669mL/min. Patients 2 This decreased clearance is not associated with increased AUC or Cmax.
Elimination Route
74% of intravenous tiotropium was excreted unchanged in urine. 14% of a dry powder inhalation dose was excreted unchanged in the urine. 24 hour urinary excretion after 21 days of 5µg once daily inhalation in patients with COPD is 18.6% and in patients with asthma is 12.8%.
Pregnancy & Breastfeeding use
Pregnancy Category C. Dilriva Inhalation Capsule 18 mcg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in Labor and Delivery: The safety and effectiveness of Dilriva Inhalation Capsule 18 mcg has not been studied during labor and delivery.
Nursing Mothers: Clinical data from nursing women exposed to Dilriva Inhalation Capsule 18 mcg are not available. caution should be exercised if administered to a nursing woman.
Contraindication
Dilriva Inhalation Capsule 18 mcg is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, including ipratropium, or to any component of this product.
Special Warning
Pediatric Use: The safety and effectiveness of Dilriva Inhalation Capsule 18 mcg in pediatric patients have not been established.
Geriatric use: No adjustment of Dilriva Inhalation Capsule 18 mcg dosage in geriatric patients is warranted.
Acute Overdose
High doses of Dilriva Inhalation Capsule 18 mcg may lead to anticholinergic signs and symptoms. Acute intoxication by inadvertent oral ingestion of Dilriva Inhalation Capsule 18 mcg Bromide unlikely since it is not well-absorbed systemically.
Storage Condition
The inhaler should be stored in a dry, cool place away from direct sunlight and heat. The canister should not be broken, punctured or burnt, even when apparently empty. Keep away from eyes. Keep out of reach of children.
Innovators Monograph
You find simplified version here Dilriva Inhalation Capsule 18 mcg
FAQ
What is Dilriva Inhalation Capsule 18 mcg used for?
Dilriva Inhalation Capsule 18 mcg is used to prevent wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease.
How safe is Dilriva Inhalation Capsule 18 mcg?
Dilriva Inhalation Capsule 18 mcg appears to be efficacious, safe, and well tolerated in patients with asthma and COPD. Dose escalation beyond 5 μg has not been shown to improve spirometric or clinical outcomes, and in asthma, it has been associated with a small increase in adverse events.
What are the common side effects of Dilriva Inhalation Capsule 18 mcg?
The common side effects of Dilriva Inhalation Capsule 18 mcg are include:
- dry mouth
- constipation
- stomach pain
- vomiting
- indigestion
- muscle pain
- nosebleed
- runny nose
- sneezing
- painful white patches in mouth
How should Dilriva Inhalation Capsule 18 mcg be used?
Dilriva Inhalation Capsule 18 mcg is usually inhaled once a day in the morning or evening. To help you remember to inhale tiotropium, inhale it around the same time every day.
Is Dilriva Inhalation Capsule 18 mcg safe during pregnancy?
The manufacturer makes no recommendation regarding use during pregnancy.The limited data available on use in pregnant women are insufficient to know this drugs risks, including the risk of fetal harm or reproductive effects.
Is Dilriva Inhalation Capsule 18 mcg safe during breastfeeding?
The manufacturer makes no recommendation regarding use during lactation.There is no information regarding this drug on the presence in human milk, the effects on a breastfed infant, or effects on milk production.
Can I drink alcohol with Dilriva Inhalation Capsule 18 mcg?
Alcohol is known to interact with a number of medications, many people taking this medication are wondering whether it is safe to consume alcohol while on Dilriva Inhalation Capsule 18 mcg treatment.
Can I drive after taking Dilriva Inhalation Capsule 18 mcg ?
This Dilriva Inhalation Capsule 18 mcg can cause dizziness. Use extreme caution when driving a vehicle or using machinery if you take this Dilriva Inhalation Capsule 18 mcg.
Can Dilriva Inhalation Capsule 18 mcg be used in asthma?
Dilriva Inhalation Capsule 18 mcg is only licensed for use in asthma when delivered using the solution for inhalation device, Respimat.
When is the best time to take Dilriva Inhalation Capsule 18 mcg?
Dilriva Inhalation Capsule 18 mcg is usually inhaled once a day in the morning or evening. To help you remember to inhale Dilriva Inhalation Capsule 18 mcg, inhale it around the same time every day.
How long does it take Dilriva Inhalation Capsule 18 mcg to work?
Dilriva Inhalation Capsule 18 mcg may take 4 to 8 weeks before you get the full benefit of this drug.
How often should I use Dilriva Inhalation Capsule 18 mcg?
Dilriva Inhalation Capsule 18 mcg is an asthma maintenance medicine taken 1 time each day. You should take 2 puffs 1 time each day,
Does Dilriva Inhalation Capsule 18 mcg reduce inflammation?
Dilriva Inhalation Capsule 18 mcg exerts anti-inflammatory effects during resistive breathing, an experimental model of severe airway obstruction.
Does Dilriva Inhalation Capsule 18 mcg stop coughing?
Dilriva Inhalation Capsule 18 mcg can actually make the cough reflex more sensitive.
What happen If I missed Dilriva Inhalation Capsule 18 mcg?
If you miss doses or don’t take the drug on schedule,Your medication may not work as well or may stop working completely.Take your dose as soon as you remember. But if you remember just a few hours before your next scheduled dose, take only one dose. Never try to catch up by taking two doses at once.
What happens If I stop taking Dilriva Inhalation Capsule 18 mcg?
If you stop taking the drug or don’t take it at all,You may have worsened shortness of breath or other breathing problems.
What happens if I overdose?
If you take overdose or too much,You could have dangerous levels of the drug in your body. If you think you’ve taken too much of this drug, call your doctor or local poison control center.
